Evidence map›Paper›PMID 35032167›Full record

ArticleInflammatory bowel diseases2022

The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis.

Gilaad G Kaplan, Fox E Underwood, Stephanie Coward, Manasi Agrawal, Ryan C Ungaro, Erica J Brenner, Richard B Gearry, Michele Kissous-Hunt, James D Lewis, Siew C Ng and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory bowel diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD.Journal of the Canadian Association of Gastroenterology · 2023
    Review
  5. Observational
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 7 countries.

Gilaad G KaplanDepartments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0003-2719-0556
Fox E UnderwoodDepartments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Stephanie CowardDepartments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0003-0675-7226
Manasi AgrawalThe Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-4729-1485
Ryan C UngaroThe Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-8687-3758
Erica J BrennerDivision of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Richard B GearryDepartment of Medicine, University of Otago, Christchurch, New Zealand.
Michele Kissous-HuntThe Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
James D LewisDepartment of Epidemiology and Biostatistics, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Siew C NgDepartment of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Hong Kong SAR, The People's Republic of China.
Jean-Francois RahierDepartment of Gastroenterology, Université Catholique de Louvain, Yvoir, Belgium.
Walter ReinischDepartment Internal Medicine III, Division Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Flavio SteinwurzDepartment of Gastroenterology, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Xian ZhangDepartment of Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Michael D KappelmanDivision of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Jean-Frederic ColombelThe Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-6472-249X
Icahn School of Medicine at Mount Sinai · USUniversity of Calgary · CAUniversity of North Carolina at Chapel Hill · USChinese University of Hong Kong · HKHospital Israelita Albert Einstein · BRMedical University of Vienna · ATUCLouvain · BEUniversity of Otago · NZUniversity of Pennsylvania · US

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
Early-life Risk Factors for Inflammatory Bowel DiseaseK23DK129762 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AGRAWAL, MANASI · 2021 to 2025
$951k
NCATS NIH HHS UL1TR002489NIDDK NIH HHS K23 DK129762
6 · The paper itself

Abstract

backgroundCases of coronavirus disease 2019 (COVID-19) have emerged in discrete waves. We explored temporal trends in the reporting of COVID-19 in inflammatory bowel disease (IBD) patients.

methodsThe Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is an international registry of IBD patients diagnosed with COVID-19. The average percent changes (APCs) were calculated in weekly reported cases of COVID-19 during the periods of March 22 to September 12, September 13 to December 12, 2020, and December 13 to July 31, 2021.

resultsAcross 73 countries, 6404 cases of COVID-19 were reported in IBD patients. COVID-19 reporting decreased globally by 4.2% per week (95% CI, -5.3% to -3.0%) from March 22 to September 12, 2020, then climbed by 10.2% per week (95% CI, 8.1%-12.3%) from September 13 to December 12, 2020, and then declined by 6.3% per week (95% CI, -7.8% to -4.7%). In the fall of 2020, weekly reporting climbed in North America (APC, 11.3%; 95% CI, 8.8-13.8) and Europe (APC, 17.7%; 95% CI, 12.1%-23.5%), whereas reporting was stable in Asia (APC, -8.1%; 95% CI, -15.6-0.1). From December 13, 2020, to July 31, 2021, reporting of COVID-19 in those with IBD declined in North America (APC, -8.5%; 95% CI, -10.2 to -6.7) and Europe (APC, -5.4%; 95% CI, -7.2 to -3.6) and was stable in Latin America (APC, -1.5%; 95% CI, -3.5% to 0.6%).

conclusionsTemporal trends in reporting of COVID-19 in those with IBD are consistent with the epidemiological patterns COVID-19 globally.

Indexed as

COVID-19Inflammatory Bowel DiseasesChronic DiseaseEuropeHumansIncidenceCOVID-19globalinflammatory bowel diseasetemporal

Identifiers

PMID35032167
PMCPMC8807298
OpenAlexW4205669504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.